Antonio Lee, Ph.D., CEO and Managing Director

Oct. 13 | 11:00am | BlueRock Therapeutics Ballroom

Gaithersburg, MD


In-person Presentation

MEDIPOST America is a wholly-owned subsidiary of MEDIPOST headquartered in Seoul, Korea. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human umbilical cord blood-derived mesenchymal stromal cells with clinical-stage assets in the disease areas of osteoarthritis, broncho-pulmonary dysplasia, and Alzheimer’s disease. MEDIPOST’s preclinical-stage pipeline includes Acute Respiratory Distress Syndrome, alopecia, and diabetic nephropathy. CARTISTEM® was approved in 2012 in Korea with the label “treatment of knee articular cartilage defects in patients with OA as a result of degenerative disease or repeated trauma”. To date, over 18,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. PNEUMOSTEM® for the prevention of Bronchopulmonary Dysplasia in premature infants demonstrated significant benefit in survival and cognitive development compared to premature infants who received standard care alone.

By using this website you agree to accept our Privacy Policy and Terms & Conditions